Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

2019; American Association for the Advancement of Science; Volume: 12; Issue: 590 Linguagem: Inglês

10.1126/scisignal.aav7259

ISSN

1937-9145

Autores

Devon R. Blake, Angelina V. Vaseva, Richard G. Hodge, McKenzie P. Kline, Thomas S.K. Gilbert, Vikas Tyagi, Daowei Huang, Gabrielle C. Whiten, Jacob E. Larson, Xiaodong Wang, Kenneth H. Pearce, Laura E. Herring, Lee M. Graves, Stephen V. Frye, Michael J. Emanuele, Adrienne D. Cox, Channing J. Der,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

CDK9 inhibitors may treat KRAS-mutant cancers by inducing MYC protein degradation.

Referência(s)